Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thomas Grussenmeyer is active.

Publication


Featured researches published by Thomas Grussenmeyer.


PLOS ONE | 2011

Integrated Epigenetics of Human Breast Cancer: Synoptic Investigation of Targeted Genes, MicroRNAs and Proteins upon Demethylation Treatment

Ramin Radpour; Zeinab Barekati; Corina Kohler; Martin Schumacher; Thomas Grussenmeyer; Paul Jenoe; Nicole Hartmann; Suzette Moes; Martin Letzkus; Johannes Bitzer; Ivan Lefkovits; Frank Staedtler; Xiao Yan Zhong

Background The contribution of aberrant DNA methylation in silencing of tumor suppressor genes (TSGs) and microRNAs has been investigated. Since these epigenetic alterations are reversible, it became of interest to determine the effects of the 5-aza-2′-deoxycytidine (DAC) demethylation therapy in breast cancer at different molecular levels. Methods and Findings Here we investigate a synoptic model to predict complete DAC treatment effects at the level of genes, microRNAs and proteins for several human breast cancer lines. The present study assessed an effective treatment dosage based on the cell viability, cytotoxicity, apoptosis and methylation assays for the investigated cell lines. A highly aggressive and a non-aggressive cell line were investigated using omics approaches such as MALDI-TOF MS, mRNA- and microRNA expression arrays, 2-D gel electrophoresis and LC-MS-MS. Complete molecular profiles including the biological interaction and possible early and late systematic stable or transient effects of the methylation inhibition were determined. Beside the activation of several epigenetically suppressed TSGs, we also showed significant dysregulation of some important oncogenes, oncomiRs and oncosuppressors miRNAs as well as drug tolerance genes/miRNAs/proteins. Conclusions In the present study, the results denote some new molecular DAC targets and pathways based on the chemical modification of DNA methylation in breast cancer. The outlined approach might prove to be useful as an epigenetic treatment model also for other human solid tumors in the management of cancer patients.


Journal of Proteome Research | 2009

Simultaneous isolation of DNA, RNA, and proteins for genetic, epigenetic, transcriptomic, and proteomic analysis.

Ramin Radpour; Michal Sikora; Thomas Grussenmeyer; Corina Kohler; Zeinab Barekati; Wolfgang Holzgreve; Ivan Lefkovits; Xiao Yan Zhong

Analysis of DNA, RNA, and proteins for downstream genetic, epigenetic, transcriptomic, and proteomic analysis holds an important place in the field of medical care and life science. This is often hampered by the limited availability of sample material. For this reason, there exists an increasing interest for simultaneous isolation of DNA, RNA and proteins from a single sample aliquot. Several kit-systems allowing such a procedure have been introduced to the market. We present an approach using the AllPrep method for simultaneous isolation of DNA, RNA and proteins from several human specimens, such as whole blood, buffy coat, serum, plasma and tissue samples. The quantification and qualification of the isolated molecular species were assessed by different downstream methods: NanoDrop for measuring concentration and purity of all molecular species; DNA and RNA LabChip for fractionation analysis of nucleic acids; quantitative PCR for quantification analysis of DNA and RNA; thymidine-specific cleavage mass array on MALDI-TOF silico-chip for epigenetic analysis; Protein LabChip and two-dimensional (2D) gel electrophoresis for proteomic analysis. With our modified method, we can simultaneously isolate DNA, RNA and/or proteins from one single sample aliquot. We could overcome to some method limitations like low quality or DNA fragmentation using reamplification strategy for performing high-throughput downstream assays. Fast and easy performance of the procedure makes this method interesting for all fields of downstream analysis, especially when using limited sample resources. The cost-effectiveness of the procedure when material is abundantly available has not been addressed. This methodological improvement enables to execute such experiments that were not performable with standard procedure, and ensures reproducible outcome.


Biotechnology and Bioengineering | 2016

Three dimensional multi‐cellular muscle‐like tissue engineering in perfusion‐based bioreactors

Giulia Cerino; Emanuele Gaudiello; Thomas Grussenmeyer; Ludovic Melly; Diana Nada Caterina Massai; Andrea Banfi; Ivan Martin; Friedrich Eckstein; Martin T. R. Grapow; Anna Marsano

Conventional tissue engineering strategies often rely on the use of a single progenitor cell source to engineer in vitro biological models; however, multi‐cellular environments can better resemble the complexity of native tissues. Previous described co‐culture models used skeletal myoblasts, as parenchymal cell source, and mesenchymal or endothelial cells, as stromal component. Here, we propose instead the use of adipose tissue‐derived stromal vascular fraction cells, which include both mesenchymal and endothelial cells, to better resemble the native stroma. Percentage of serum supplementation is one of the crucial parameters to steer skeletal myoblasts toward either proliferation (20%) or differentiation (5%) in two‐dimensional culture conditions. On the contrary, three‐dimensional (3D) skeletal myoblast culture often simply adopts the serum content used in monolayer, without taking into account the new cell environment. When considering 3D cultures of mm‐thick engineered tissues, homogeneous and sufficient oxygen supply is paramount to avoid formation of necrotic cores. Perfusion‐based bioreactor culture can significantly improve the oxygen access to the cells, enhancing the viability and the contractility of the engineered tissues. In this study, we first investigated the influence of different serum supplementations on the skeletal myoblast ability to proliferate and differentiate during 3D perfusion‐based culture. We tested percentages of serum promoting monolayer skeletal myoblast‐proliferation (20%) and differentiation (5%) and suitable for stromal cell culture (10%) with a view to identify the most suitable condition for the subsequent co‐culture. The 10% serum medium composition resulted in the highest number of mature myotubes and construct functionality. Co‐culture with stromal vascular fraction cells at 10% serum also supported the skeletal myoblast differentiation and maturation, hence providing a functional engineered 3D muscle model that resembles the native multi‐cellular environment. Biotechnol. Bioeng. 2016;113: 226–236.


Journal of Proteomics | 2011

Proteome analysis in cardiovascular pathophysiology using Dahl rat model.

Thomas Grussenmeyer; Silvia Meili-Butz; Volker Roth; Thomas Dieterle; Marijke Brink; Bernhard Winkler; Peter Matt; Thierry Carrel; Friedrich S. Eckstein; Ivan Lefkovits; Martin Grapow

Dahl salt-sensitive (DS) and salt-resistant (DR) inbred rat strains represent a well established animal model for cardiovascular research. Upon prolonged administration of high-salt-containing diet, DS rats develop systemic hypertension, and as a consequence they develop left ventricular hypertrophy, followed by heart failure. The aim of this work was to explore whether this animal model is suitable to identify biomarkers that characterize defined stages of cardiac pathophysiological conditions. The work had to be performed in two stages: in the first part proteomic differences that are attributable to the two separate rat lines (DS and DR) had to be established, and in the second part the process of development of heart failure due to feeding the rats with high-salt-containing diet has to be monitored. This work describes the results of the first stage, with the outcome of protein expression profiles of left ventricular tissues of DS and DR rats kept under low salt diet. Substantial extent of quantitative and qualitative expression differences between both strains of Dahl rats in heart tissue was detected. Using Principal Component Analysis, Linear Discriminant Analysis and other statistical means we have established sets of differentially expressed proteins, candidates for further molecular analysis of the heart failure mechanisms.


European Journal of Medical Research | 2015

Rapamycin impairs endothelial cell function in human internal thoracic arteries

David Reineke; Else Müller-Schweinitzer; Bernhard Winkler; Donatina Kunz; Moritz A. Konerding; Thomas Grussenmeyer; Thierry Carrel; Friedrich S. Eckstein; Martin Grapow

BackgroundDefinitive fate of the coronary endothelium after implantation of a drug-eluting stent remains unclear, but evidence has accumulated that treatment with rapamycin-eluting stents impairs endothelial function in human coronary arteries. The aim of our study was to demonstrate this phenomenon on functional, morphological and biochemical level in human internal thoracic arteries (ITA) serving as coronary artery model.MethodsAfter exposure to rapamycin for 20 h, functional activity of ITA rings was investigated using the organ bath technique. Morphological analysis was performed by scanning electron microscopy and evaluated by two independent observers in blinded fashion. For measurement of endothelial nitric oxide synthase (eNOS) release, mammalian target of rapamycin (mTOR) and protein kinase B (PKB) (Akt) activation, Western blotting on human mammary epithelial cells-1 and on ITA homogenates was performed.ResultsComparison of the acetylcholine-induced relaxation revealed a significant concentration-dependent decrease to 66 ± 7 % and 36 ± 7 % (mean ± SEM) after 20-h incubation with 1 and 10 μM rapamycin. Electron microscopic evaluation of the endothelial layer showed no differences between controls and samples exposed to 10 μM rapamycin. Western blots after 20-h incubation with rapamycin (10 nM–1 μM) revealed a significant and concentration-dependent reduction of p (Ser 1177)-eNOS (down to 38 ± 8 %) in human mammary epithelial cells (Hmec)-1. Furthermore, 1 μM rapamycin significantly reduced activation of p (Ser2481)-mTOR (58 ± 11 %), p (Ser2481)-mTOR (23 ± 4 %) and p (Ser473)-Akt (38 ± 6 %) in ITA homogenates leaving Akt protein levels unchanged.ConclusionsThe present data suggests that 20-h exposure of ITA rings to rapamycin reduces endothelium-mediated relaxation through down-regulation of Akt-phosphorylation via the mTOR signalling axis within the ITA tissue without injuring the endothelial cell layer.


Asian Cardiovascular and Thoracic Annals | 2007

Proteomics of Ascending Aortic Aneurysm with Bicuspid or Tricuspid Aortic Valve

Peter Matt; Anne von Orelli; Franziska Bernet; Thomas Grussenmeyer; Ivan Lefkovits; Hans-Reinhard Zerkowski

Bicuspid aortic valve is often associated with lesions of the ascending aorta, which differ histologically from those in tricuspid valve patients. We undertook proteomic analyses to assess differences at the proteome level. Aortic samples were collected from 20 patients undergoing aortic valve and/or ascending aortic replacement; 9 had a bicuspid valve: 5 with aortic aneurysm (diameter > 50 mm) and 4 without dilation; 11 had a tricuspid valve: 6 with aortic aneurysm and 5 without dilation. Patients with histologically proven connective tissue disorders were excluded. Samples were dissected, solubilized, and subjected to 2-dimensional gel electrophoresis. Gel patterns showed an average of 580 protein spots in samples from bicuspid valve patients, and 564 spots in those with tricuspid valves. Comparative analysis revealed a correlation coefficient of 0.93 for protein expression in the bicuspid valve group compared to the tricuspid group. Three protein spots were significantly over-expressed and 4 were significantly down-regulated in the bicuspid group compared to the tricuspid group. The lowest correlation in protein expression was between non-dilated aortic tissues. These differences between aortic tissues of bicuspid and tricuspid valve patients suggest that mechanisms of aortic dilation might differ, at least in part, between such patients.


Journal of Tissue Engineering and Regenerative Medicine | 2014

Engineering of a contractile cardiac patch with an intrinsic vasculogenic potential

Giulia Cerino; Emanuele Gaudiello; Ludovic Melly; Thomas Grussenmeyer; Martin T. R. Grapow; Ivan Martin; Diana Nada Caterina Massai; Friedrich Eckstein; Andrea Banfi; A. Scherberich; Anna Marsano

Introduction: Decellularized engineered extracellular matrices (ECM) are used in a variety of regenerative medicine applications. Existing decellularization strategies rely on cell lysis and generally result in a variable but significant impairment of the ECM structure/composition. As an alternative, we aimed at activating the apoptotic pathway in order to decellularize engineered matrices while preserving their osteo-inductive properties [1]. Materials and methods: We generated a death-inducible, immortalized human Mesenchymal Stromal Cell (hMSC) line [2]. Cells were seeded on ceramic scaffolds and cultured for 4 weeks in osteogenic medium in a 3D perfusion bioreactor system (U-cup, Cellec). The ECM was decellularized by direct supply of the apoptotic inducer in the 3D culture system. Grafts were implanted in a rat cranial defect model to assess their regenerative potential after 12 weeks. Results: Cells were successfully seeded and differentiated, leading to deposition of a dense ECM during 3D culture. The apoptosis induction allowed for efficient decellularization while preserving the secreted matrix. These “apoptized” cell-free ECM coated constructs induced superior bone regeneration than control materials (Fig. 2). Areas of de novo bone formation not connected with surrounding bone suggest osteoinductive properties of the grafts.


Journal of Proteome Research | 2004

Proteomics strategies in cardiovascular research.

Hans-Reinhard Zerkowski; Thomas Grussenmeyer; Peter Matt; Martin Grapow; Stefan Engelhardt; Ivan Lefkovits


Journal of Proteome Research | 2007

Turnover Proteome of Human Atrial Trabeculae

Florian M. Lampert; Peter Matt; Martin Grapow; Ivan Lefkovits; Hans-Reinhard Zerkowski; Thomas Grussenmeyer


Cryobiology | 2007

Impact of freezing/thawing procedures on the post-thaw viability of cryopreserved human saphenous vein conduits

Else Müller-Schweinitzer; Heinz Striffeler; Thomas Grussenmeyer; David Reineke; Erika Glusa; Martin Grapow

Collaboration


Dive into the Thomas Grussenmeyer's collaboration.

Top Co-Authors

Avatar

Ivan Lefkovits

Basel Institute for Immunology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Peter Matt

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrea Banfi

University Hospital of Basel

View shared research outputs
Top Co-Authors

Avatar

Anna Marsano

University Hospital of Basel

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge